Floatz logo

Panitumumab

Colorectal Cancer

MSPU des 3 Provincesmonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
59/ 100

Competitive context

713 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Marble Dust
James Varani
Phase 2/3BB
Orectalip
Sinphar Pharmaceutical Co., Ltd
Phase 4BB
Fluorouracilum
UNICANCER
Phase 4BB
Levofolinic Acid
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Panitumumab is also rated in:

neoplasmActive
BBB
Indicative · Phase 2
73 / 100
View asset →
rectal carcinomaDormant
BB
Indicative · Phase 2
67 / 100
View asset →
colon adenocarcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →